Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 8 April 2019, 10:43 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Start Your Day With a Sparkling Pop!

Containing 75 Lemons Worth of Vitamin C and 50% Less Calories!

TOKYO, Apr 8, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims, in Japan on Tuesday, April 9.


Chocola BB Sparkling Kiwi & Lemon Flavor is a new carbonated beverage classified by the Japanese Consumer Affairs Agency as a Food with Nutrient Function Claims (Niacin), and is the newest product flavor of the Chocola BB Sparkling series which has been well received mainly by working women since the series? initial launch in 2011. The drink contains five ingredients that help bring out women?s beauty from within, including 1500 mg of vitamin C which is equivalent to 75 lemons, in addition to vitamin B1, B6, iron, as well as niacin to help maintain the health of skin and mucosal membranes. Compared to the original Chocola BB Sparkling Grapefruit & Peach Flavor, calories have been reduced by 50% (24kcal).

By adding the new Chocola BB Sparkling Kiwi & Lemon Flavor with its fresh taste to the Chocola BB Sparkling lineup, consumers will be able to enjoy a choice between two flavors to match their personal needs for refreshment.

Eisai continues to provide the Chocola BB family of products to respond to the diverse needs of women and support a greater number of people to achieve health and beauty in their everyday lives.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: